Rigolin, G. M., Olimpieri, P. P., Summa, V., Celant, S., Scarfò, L., Tognolo, L., . . . Russo, P. (2023). Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: A nationwide registry study from the Italian Medicines Agency. Nature Publishing Group.
Chicago Style (17th ed.) CitationRigolin, Gian Matteo, et al. Outcomes in Patients with Chronic Lymphocytic Leukemia and TP53 Aberration Who Received First-line Ibrutinib: A Nationwide Registry Study from the Italian Medicines Agency. Nature Publishing Group, 2023.
MLA (9th ed.) CitationRigolin, Gian Matteo, et al. Outcomes in Patients with Chronic Lymphocytic Leukemia and TP53 Aberration Who Received First-line Ibrutinib: A Nationwide Registry Study from the Italian Medicines Agency. Nature Publishing Group, 2023.